Cargando…

Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study

OBJECTIVE: To compare a once-daily long-acting β(2) agonist (indacaterol 150 µg) with a once-daily long-acting anticholinergic (tiotropium 5 µg) in terms of their effects on exercise endurance (limit of tolerance, Tlim) in patients with moderate COPD. Secondary endpoints were their effects on lung h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berton, Danilo Cortozi, dos Santos, Álvaro Huber, Bohn, Ivo, de Lima, Rodrigo Quevedo, Breda, Vanderléia, Teixeira, Paulo José Zimermann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094874/ https://www.ncbi.nlm.nih.gov/pubmed/27812637 http://dx.doi.org/10.1590/S1806-37562015000000334

Ejemplares similares

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
por: Fujimoto, Keisaku, et al.
Publicado: (2017)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
por: Molino, Antonio, et al.
Publicado: (2017)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Comparison of Clinical Efficacy and Safety between Indacaterol and Tiotropium in COPD: Meta-Analysis of Randomized Controlled Trials
por: Kim, Jung Soo, et al.
Publicado: (2015)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
por: Rhee, Chin Kook, et al.
Publicado: (2017)

Is this asthma, COPD, or both?
por: Neder, José Alberto, et al.
Publicado: (2021)

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
por: Kaplan, Alan, et al.
Publicado: (2019)

The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study – the FAVOR study
por: Kardos, Peter, et al.
Publicado: (2017)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial
por: Beaulieu, Jessie, et al.
Publicado: (2020)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

Absence of airflow obstruction on spirometry: can it still be COPD?
por: Neder, José Alberto, et al.
Publicado: (2020)

Out-of-proportion dyspnea and exercise intolerance in mild COPD
por: Neder, José Alberto, et al.
Publicado: (2021)

Using the pulmonary function laboratory to assist in disease management: COPD
por: Neder, José Alberto, et al.
Publicado: (2023)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

Role of tiotropium in the treatment of COPD
por: Rice, Kathryn L, et al.
Publicado: (2007)

Safety, tolerability and risk benefit analysis of tiotropium in COPD
por: Oba, Yuji, et al.
Publicado: (2008)

Can bronchodilators improve exercise tolerance in COPD patients without dynamic hyperinflation?
por: Scuarcialupi, Maria Enedina Aquino, et al.
Publicado: (2014)

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)
por: Watz, Henrik, et al.
Publicado: (2016)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease
por: Inui, Naoki, et al.
Publicado: (2015)

COPD: more treatment will translate to better breathing. Will it?
por: Teixeira, Paulo José Zimermann, et al.
Publicado: (2019)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
por: Vogelmeier, Claus F., et al.
Publicado: (2017)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Effect of the expiratory positive airway pressure on dynamic hyperinflation and exercise capacity in patients with COPD: a meta-analysis
por: Cardoso, Dannuey Machado, et al.
Publicado: (2020)

Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance
por: Ambrosino, Nicolino, et al.
Publicado: (2008)

Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial
por: Troosters, Thierry, et al.
Publicado: (2014)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
por: Lan, Ying, et al.
Publicado: (2023)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
por: Singh, Dave, et al.
Publicado: (2022)

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
por: Kalberg, Chris, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t9661msip1gm3err2regn0gpb9